- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01827826
Call-2-Health: Preventing Type II Diabetes (C2H)
Translating the Diabetes Prevention Project (DPP) in a Health Maintenance Organization (HMO) Setting
It is estimated that 30 million U.S. adults will have type 2 diabetes by 2050. Contributing to this national trend is the obesity epidemic. Three randomized trials have demonstrated that intensive behavioral interventions can prevent or delay the onset of diabetes. The purpose of this pilot study is to inform a future randomized, controlled Phase III trial of a population-based, telephonic, exercise and weight loss intervention to translate the findings of the Diabetes Prevention Program into practice. The telephonic intervention will be compared to usual care (30 participants in each group). The investigators will deliver the intervention in 12 weekly, 20-minute calls, with four subsequent maintenance calls, for a total of 16 calls over 24 weeks. Study outcomes will be measured at baseline and at 12 and 24 weeks.
For this planning grant the investigators do not have an overall hypothesis. The investigators' goal is to develop and test whether it is possible to do exercise and weight loss
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Washington
-
Seattle, Washington, Spojené státy, 98101
- Group Health Research Institute
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Male or female
- Age 40-74
- Receives primary care at Group Health Central, Rainier, or Poulsbo clinics in the greater Seattle area
- Can walk for more than 10 minutes
- Fasting plasma glucose (FPG) 105-125 mg/dl or glycolated hemoglobin (HbA1C) 5.7-6.4
- Body Mass Index (BMI) 25 kg/m2 or greater
Exclusion Criteria:
- Type 1 or 2 diabetes
- FPG > 125 mg/dl or < 105mg/dl at screening blood draw
- HbA1C > 6.4 or < 5.7 at screening blood draw
- Systolic blood pressure > 210 mmHg at the baseline clinic visit
- Exercise ≥ 30 minutes/day, at least five days a week
- Current participation in another structured weight loss treatment program or another intervention study
- Severe concurrent disease
- Unavailable for the 24-week study period
- Unable to read or speak English
- Pregnant or planning to become pregnant.
- Mentally or legally incapacitated such that informed consent cannot be obtained.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Aktivní komparátor: Intervention
Participants assigned to the intervention group worked with the study interventionist over the phone to reduce their risk for developing Diabetes Mellitus, Type 2. The intervention lasted for 24 weeks, with weekly phone calls for the first 12 weeks and 4 maintenance calls over the second 12 weeks.
Study measurements were taken at baseline, 12 weeks, 24 weeks, and 52 weeks.
After 24 weeks, the investigators randomly divided the intervention group in half.
The first group did not receive any more phone calls from the interventionist.
The second group continued to receive monthly 20-minute phone calls from the interventionist.
At 52 weeks post-baseline participants from both groups had their labs drawn, wore a pedometer for 3 days, and called in with a self-reported weight.
|
Participants assigned to the intervention group received a total of 16 phone calls from the study interventionist over 24 weeks.
The first 12 weeks was the intervention phase and calls were made weekly.
The second 12 weeks was the maintenance phase and calls were made every 3 weeks.
After 24 weeks, the investigators continued to follow this group for 52 weeks post-randomization, allowing half of the group to continue to receive monthly maintenance calls while the other half received no further calls.
The study interventionist used behavior modification techniques to encourage intervention group participants to adopt healthy eating and exercise habits so that improvement might be seen in fasting glucose, glycated hemoglobin (HbA1c), weight, and waist/hip measurements.
|
Žádný zásah: Control
Participants randomized into this group did not receive any intervention, although they were encouraged to follow-up with their doctor and follow through with usual clinical care.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Program feasibility: Uptake
Časové okno: Baseline
|
Measured by the number of people who consent to be in the study compared to the number who were eligible
|
Baseline
|
Program feasibility: Attendance
Časové okno: 12 weeks
|
Measured by the number of participants who return for their 12 week clinic visit
|
12 weeks
|
Program feasibility: Attendance
Časové okno: 24 weeks
|
Measured by the number of participants who return for their 24 week clinic visit
|
24 weeks
|
Program feasibility: Attendance
Časové okno: 52 weeks
|
Measured by the number of participants who complete their 52 week assignments (3 day pedometer, self-reported weight, fasting blood draw)
|
52 weeks
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Fasting glucose
Časové okno: Baseline, 12 weeks, 24 weeks, 52 weeks
|
Measured via a fasting blood draw
|
Baseline, 12 weeks, 24 weeks, 52 weeks
|
Waist circumference
Časové okno: Baseline, 12 weeks, 24 weeks
|
in centimeters
|
Baseline, 12 weeks, 24 weeks
|
Blood pressure
Časové okno: Baseline, 12 weeks, 24 weeks
|
Measured using an automated clinical blood pressure monitor (Brand name: Omron, Model number HEM-907XL)
|
Baseline, 12 weeks, 24 weeks
|
Healthy eating habits
Časové okno: Baseline, 12 weeks, 24 weeks
|
Assessed using the Food Frequency Questionnaire
|
Baseline, 12 weeks, 24 weeks
|
Weight loss
Časové okno: Baseline, 12 weeks, 24 weeks, 52 weeks
|
Weight measured in kilograms
|
Baseline, 12 weeks, 24 weeks, 52 weeks
|
Changes in activity
Časové okno: Baseline, 12 weeks, 24 weeks, 52 weeks
|
Measured using the Modifiable Activity Questionnaire (MAQ)
|
Baseline, 12 weeks, 24 weeks, 52 weeks
|
Glycated hemoglobin (A1C)
Časové okno: Baseline, 12 weeks, 24 weeks, 52 weeks
|
Measured via a fasting blood draw
|
Baseline, 12 weeks, 24 weeks, 52 weeks
|
Total cholesterol (TC)
Časové okno: Baseline, 12 weeks, 24 weeks, 52 weeks
|
Measured via a fasting blood draw
|
Baseline, 12 weeks, 24 weeks, 52 weeks
|
High density lipoprotein (HDL)
Časové okno: Baseline, 12 weeks, 24 weeks, 52 weeks
|
Measured via a fasting blood draw
|
Baseline, 12 weeks, 24 weeks, 52 weeks
|
Low density lipoprotein (LDL)
Časové okno: Baseline, 12 weeks, 24 weeks, 52 weeks
|
Measured via fasting blood draw.
|
Baseline, 12 weeks, 24 weeks, 52 weeks
|
Body Mass Index (BMI)
Časové okno: Baseline, 12 weeks, 24 weeks, 52 weeks
|
Baseline, 12 weeks, 24 weeks, 52 weeks
|
|
Physical activity level
Časové okno: Baseline, 12 weeks, 24 weeks, 52 weeks
|
Participants wore a blinded pedometer for 3 days
|
Baseline, 12 weeks, 24 weeks, 52 weeks
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Katherine Newton, PhD, Group Health Research Institute
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 184802-16
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Diabetes mellitus, typ 2
-
Hoffmann-La RocheDokončenoDiabetes 2. typu, Diabetes 1. typuRakousko, Spojené království
-
West China HospitalDokončeno
-
Services Hospital, LahoreDokončeno
-
Griffin HospitalCalifornia Walnut CommissionDokončenoDIABETES MELLITUS TYP 2Spojené státy
-
Novo Nordisk A/SNáborDiabetes, typ 2Spojené státy, Indie, Španělsko, Polsko, Jižní Afrika, Bulharsko, Německo, Japonsko, Portoriko
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Churchill HospitalDokončenoDiabetes, typ 2Spojené království
-
Kyowa Kirin Co., Ltd.Dokončeno
-
Inova Health Care ServicesStaženo
-
TABREJ MUJAWARDokončeno
-
University of MichiganAgency for Healthcare Research and Quality (AHRQ)Dokončeno